Medexus Pharmaceuticals Future Growth
Future criteria checks 5/6
Medexus Pharmaceuticals is forecast to grow earnings and revenue by 59.5% and 14.3% per annum respectively. EPS is expected to grow by 59.3% per annum. Return on equity is forecast to be 30% in 3 years.
Key information
59.5%
Earnings growth rate
59.31%
EPS growth rate
| Pharmaceuticals earnings growth | 12.2% |
| Revenue growth rate | 14.3% |
| Future return on equity | 30.03% |
| Analyst coverage | Good |
| Last updated | 12 Jun 2026 |
Recent future growth updates
Recent updates
Narrative Update • Jun 02
MDP: Ongoing Share Repurchases Will Support Upside Potential
Analysts have adjusted their CA$ price target on Medexus Pharmaceuticals, citing updated assumptions for discount rates, revenue growth, profit margins and future P/E as the key drivers of the revised valuation. What's in the News Medexus reported an operational update on the commercialization of GRAFAPEX (treosulfan) for Injection in the United States, with 56 healthcare institutions having granted positive formulary inclusion decisions as of March 31, 2026, and 64 transplant centers having ordered the product for procedures.Narrative Update • Apr 27
MDP: Share Repurchases And Transplant Center Adoption Will Support Upside
Analysts have modestly raised their CA$ price target on Medexus Pharmaceuticals, citing slightly higher modeled revenue growth of 21.21% and a profit margin assumption of 24.84%, while keeping the fair value and discount rate unchanged. What's in the News Medexus provided an operational update on the commercialization of GRAFAPEX (treosulfan) for Injection in the United States, including recent progress with transplant center formulary decisions and ordering activity.Narrative Update • Apr 09
MDP: Share Buyback And Higher Future P E Multiple Will Support Upside
Analysts have adjusted their CA$ price target on Medexus Pharmaceuticals, citing updated assumptions around revenue growth, profit margins, and future P/E that refine their outlook on the company’s valuation. What's in the News Medexus Pharmaceuticals completed a share buyback tranche covering 191,900 shares, equal to 0.59% of its shares, between November 20, 2025 and December 31, 2025 (Key Developments).Narrative Update • Mar 26
MDP: Share Repurchase And Higher Margin Outlook Will Support Future Upside
Analysts have modestly lifted their price target on Medexus Pharmaceuticals to CA$8.00, reflecting slightly higher modeled revenue growth, a small uptick in profit margin assumptions, and a marginally lower future P/E multiple. What's in the News Medexus Pharmaceuticals completed a share repurchase of 191,900 shares from November 20, 2025 to December 31, 2025, representing 0.59% of its shares, for a total of CA$0.52 million under its previously announced buyback program (Key Developments).Narrative Update • Mar 11
MDP: Share Repurchase And Higher Margin Outlook Will Support Future Upside
Analysts have raised their CA$ price target on Medexus Pharmaceuticals, citing slightly stronger modeled revenue growth of 19.57% and a profit margin of 27.71%, along with a modestly lower forward P/E of 4.80x in their updated assumptions. What's in the News Medexus Pharmaceuticals completed a share repurchase of 191,900 shares, representing 0.59% of shares, for CAD 0.52 million under its buyback program announced on November 20, 2025 (Key Developments).Narrative Update • Feb 25
MDP: Share Repurchase And Higher Margin Outlook Will Support Future Upside
Analysts have revised their CA$ price target on Medexus Pharmaceuticals upward, reflecting updated assumptions that include modeled revenue growth of 19.35%, a profit margin of 27.36% and a slightly lower forward P/E of 4.85x. What's in the News Medexus Pharmaceuticals completed a share repurchase of 191,900 shares, representing 0.59% of its outstanding equity, for a total cost of CA$0.52 million under the buyback announced on November 20, 2025 (Key Developments).Narrative Update • Feb 10
MDP: Share Repurchase Plan Will Support Higher Future Shareholder Value
Analysts have modestly adjusted their price target on Medexus Pharmaceuticals, citing updated assumptions around revenue growth of about 17.94%, profit margin of about 25.99% and a future P/E of about 5.10x. Together, these figures inform a refreshed fair value view of US$8.00 per share.Narrative Update • Jan 26
MDP: Share Repurchase Plan Will Support Stronger Future Shareholder Returns
Analysts have lifted their price target on Medexus Pharmaceuticals to US$8.00 from US$8.00, citing slightly higher modeled revenue growth, a modestly stronger profit margin outlook, and a small adjustment to the future P/E assumption. What's in the News Medexus Pharmaceuticals has announced a share repurchase program that allows the company to buy back up to 2,983,650 shares, or 9.2% of its issued share capital, with all repurchased shares set to be cancelled.Narrative Update • Jan 11
MDP: Share Repurchase Program Will Support Stronger Future Shareholder Returns
Analysts have reaffirmed their price target on Medexus Pharmaceuticals at US$8.00, citing updated assumptions for revenue growth, profit margins, and future P/E that adjust their overall outlook while keeping the fair value level unchanged. What's in the News Medexus Pharmaceuticals Inc.Analysis Article • Jan 03
Does Medexus Pharmaceuticals (TSE:MDP) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Narrative Update • Dec 16
MDP: Share Repurchase Program Will Drive Stronger Future Shareholder Returns
Analysts have raised their price target for Medexus Pharmaceuticals to approximately $8.00 per share from about $6.00, citing expectations of stronger revenue growth, a substantial improvement in profit margins, and a lower projected future P/E multiple that enhances the stock's valuation appeal. What's in the News Medexus Pharmaceuticals Inc.
Narrative Update • Aug 20
US Transplant Centers Will Drive Specialty Care Adoption
Despite notable improvements in net profit margin and revenue growth forecasts, the consensus analyst price target for Medexus Pharmaceuticals has been revised downward from CA$7.11 to CA$6.71. What's in the News Medexus Pharmaceuticals received approval from US CMS for New Technology Add-On Payment (NTAP) reimbursement for GRAFAPEX™ (treosulfan) for Injection for fiscal year 2026.Narrative Update • Aug 06
US Transplant Centers Will Drive Specialty Care Adoption
The notable increase in Medexus Pharmaceuticals' consensus price target is primarily driven by a significant rise in its future P/E valuation, with fair value revised upward from CA$6.50 to CA$7.11. Valuation Changes Summary of Valuation Changes for Medexus Pharmaceuticals The Consensus Analyst Price Target has risen from CA$6.50 to CA$7.11.Analysis Article • May 04
Earnings Tell The Story For Medexus Pharmaceuticals Inc. (TSE:MDP) As Its Stock Soars 28%
Those holding Medexus Pharmaceuticals Inc. ( TSE:MDP ) shares would be relieved that the share price has rebounded 28...
New Narrative • Feb 19
FDA Approval Of GRAFAPEX Will Unlock Market Potential With 7 Years Exclusivity
Successful FDA approval for GRAFAPEX is expected to significantly increase revenue, providing a robust new stream with its granted exclusivity.Analysis Article • Jan 19
Investors Appear Satisfied With Medexus Pharmaceuticals Inc.'s (TSE:MDP) Prospects As Shares Rocket 52%
Despite an already strong run, Medexus Pharmaceuticals Inc. ( TSE:MDP ) shares have been powering on, with a gain of...Analysis Article • Dec 05
After Leaping 31% Medexus Pharmaceuticals Inc. (TSE:MDP) Shares Are Not Flying Under The Radar
Medexus Pharmaceuticals Inc. ( TSE:MDP ) shares have had a really impressive month, gaining 31% after a shaky period...Analysis Article • Nov 05
Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysis Article • Aug 19
There May Be Reason For Hope In Medexus Pharmaceuticals' (TSE:MDP) Disappointing Earnings
Medexus Pharmaceuticals Inc.'s ( TSE:MDP ) stock was strong despite it releasing a soft earnings report last week. We...Analysis Article • Aug 10
Medexus Pharmaceuticals Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Medexus Pharmaceuticals Inc. ( TSE:MDP ) just released its latest quarterly results and things are looking bullish. It...Analysis Article • Jul 31
Medexus Pharmaceuticals Inc. (TSE:MDP) Shares Fly 29% But Investors Aren't Buying For Growth
Medexus Pharmaceuticals Inc. ( TSE:MDP ) shareholders have had their patience rewarded with a 29% share price jump in...Analysis Article • Jun 15
The Market Doesn't Like What It Sees From Medexus Pharmaceuticals Inc.'s (TSE:MDP) Revenues Yet
When you see that almost half of the companies in the Pharmaceuticals industry in Canada have price-to-sales ratios (or...Analysis Article • Apr 25
Here's Why Medexus Pharmaceuticals (TSE:MDP) Has A Meaningful Debt Burden
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysis Article • Mar 03
Revenues Working Against Medexus Pharmaceuticals Inc.'s (TSE:MDP) Share Price Following 26% Dive
The Medexus Pharmaceuticals Inc. ( TSE:MDP ) share price has softened a substantial 26% over the previous 30 days...Analysis Article • Jan 06
Medexus Pharmaceuticals Inc.'s (TSE:MDP) Shares Leap 89% Yet They're Still Not Telling The Full Story
Medexus Pharmaceuticals Inc. ( TSE:MDP ) shares have had a really impressive month, gaining 89% after a shaky period...Analysis Article • Oct 11
Here's Why Medexus Pharmaceuticals (TSE:MDP) Has Caught The Eye Of Investors
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Analysis Article • Sep 11
Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 3/31/2029 | 161 | 38 | N/A | 44 | 3 |
| 3/31/2028 | 138 | 24 | N/A | 29 | 4 |
| 3/31/2027 | 113 | 8 | N/A | 16 | 6 |
| 3/31/2026 | 99 | 0 | N/A | 19 | 6 |
| 12/31/2025 | 99 | 0 | 10 | 17 | N/A |
| 9/30/2025 | 104 | 0 | 13 | 16 | N/A |
| 6/30/2025 | 106 | 1 | 14 | 20 | N/A |
| 3/31/2025 | 108 | 2 | 21 | 24 | N/A |
| 12/31/2024 | 110 | 4 | 20 | 23 | N/A |
| 9/30/2024 | 105 | 2 | 19 | 22 | N/A |
| 6/30/2024 | 109 | 1 | 22 | 23 | N/A |
| 3/31/2024 | 113 | 0 | 18 | 19 | N/A |
| 12/31/2023 | 116 | 6 | 21 | 21 | N/A |
| 9/30/2023 | 119 | 5 | 13 | 13 | N/A |
| 6/30/2023 | 117 | 3 | 6 | 7 | N/A |
| 3/31/2023 | 108 | 1 | -2 | -1 | N/A |
| 12/31/2022 | 100 | -11 | -3 | -2 | N/A |
| 9/30/2022 | 92 | -11 | -3 | -1 | N/A |
| 6/30/2022 | 82 | 2 | 0 | 2 | N/A |
| 3/31/2022 | 77 | -3 | -9 | -1 | N/A |
| 12/31/2021 | 74 | -8 | -17 | -1 | N/A |
| 9/30/2021 | 77 | -20 | -18 | -1 | N/A |
| 6/30/2021 | 77 | -31 | -21 | -5 | N/A |
| 3/31/2021 | 80 | -28 | -6 | 5 | N/A |
| 12/31/2020 | 79 | -19 | -1 | 0 | N/A |
| 9/30/2020 | 69 | -9 | 1 | 1 | N/A |
| 6/30/2020 | 64 | -7 | 1 | 1 | N/A |
| 3/31/2020 | 56 | -5 | -3 | -2 | N/A |
| 12/31/2019 | 47 | -4 | -1 | 0 | N/A |
| 9/30/2019 | 45 | -3 | N/A | 0 | N/A |
| 6/30/2019 | 36 | -6 | N/A | -1 | N/A |
| 3/31/2019 | 25 | -5 | N/A | -1 | N/A |
| 12/31/2018 | 17 | -5 | N/A | -2 | N/A |
| 9/30/2018 | 9 | -5 | N/A | -1 | N/A |
| 6/30/2018 | 8 | -2 | N/A | -2 | N/A |
| 3/31/2018 | 8 | -3 | N/A | -3 | N/A |
| 12/31/2017 | 8 | -3 | N/A | -3 | N/A |
| 9/30/2017 | 7 | -3 | N/A | -4 | N/A |
| 6/30/2017 | 6 | -3 | N/A | -4 | N/A |
| 3/31/2017 | 5 | -1 | N/A | -1 | N/A |
| 12/31/2016 | 4 | 1 | N/A | 1 | N/A |
| 9/30/2016 | 3 | 1 | N/A | 1 | N/A |
| 6/30/2016 | 3 | 1 | N/A | 1 | N/A |
| 3/31/2016 | 3 | -2 | N/A | -1 | N/A |
| 12/31/2015 | 3 | -4 | N/A | -3 | N/A |
| 9/30/2015 | 2 | -4 | N/A | -3 | N/A |
| 6/30/2015 | 2 | -5 | N/A | -3 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MDP is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3%).
Earnings vs Market: MDP is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: MDP is expected to become profitable in the next 3 years.
Revenue vs Market: MDP's revenue (14.3% per year) is forecast to grow faster than the Canadian market (4.6% per year).
High Growth Revenue: MDP's revenue (14.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MDP's Return on Equity is forecast to be high in 3 years time (30%)
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/14 03:22 |
| End of Day Share Price | 2026/06/12 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Medexus Pharmaceuticals Inc. is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Scott Henry | Alliance Global Partners |
| Tania Armstrong-Whitworth | ATB Cormark Historical (Cormark Securities) |
| David Martin | Bloom Burton & Co. |